FDA Approves Egrifta (tesamorelin for injection): First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-infected Patients with Lipodystrophy
Links shared publicly online about this topic.
- 734total visits
FDA Approves Egrifta (tesamorelin for injection): First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-infected Patients with Lipodystrophy
View full resource at drugs.com
Most Recently Shared on November 12, 2010 at 1:25 am By:
FDA Approves Egrifta for the Reduction of Excess Abdominal Fat in HIV Patients with Lipodystrophy - http://bit.ly/bYTUCU
FDA Approves EGRIFTA™ (tesamorelin For Injection): First And Only Treatment For The Reduction Of Excess Abdominal Fat In HIV-infected Patients
medicalnewstoday.com — “EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced that the U.S. Food and Drug Administration (FDA) has approved EGRIFTA™ (tesamorelin for injection) as the first an” View full resource at medicalnewstoday.com
Most Recently Shared on November 12, 2010 at 7:05 pm By:
FDA Approves EGRIFTA™ (tesamorelin For Injection): First And Only Treatment For The Reduction Of Excess Abdomina... http://mnt.to/3Mvz
FDA Approves Egrifta (tesamorelin for injection): First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-infected Patients with Lipodystrophy
drugs.com — “Egrifta (tesamorelin) is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Includes Egrifta side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on November 12, 2010 at 12:10 am By:
Drugs and Devices OW OW Health
FDA Approves Egrifta (tesamorelin for injection): First and Only Treatment for the Reduction of Excess Abd... http://bit.ly/aGIPwA #drug
Advertisement
